Who Paid My Doc
Thomas Youm
Sports Medicine Englewood, NJ Medical Doctor
NPI 1134116445 CMS profile 187577
34 S Dean St, Ste 202, Englewood, NJ 07631
General payments
$221,250
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,000
Through program year 2025, Thomas Youm of Englewood, NJ is reported in the CMS Open Payments database as having received $221,250 across 293 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $82,794 | 41 | |
| 2024 | General | $18,969 | 30 | |
| 2023 | General | $30,634 | 44 | |
| 2022 | General | $62,487 | 89 | |
| 2021 | General | $5,048 | 31 | |
| 2020 | General | $5,743 | 19 | |
| 2019 | General | $15,575 | 39 |
Beside peers
- Thomas Youm
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Thomas Youm were reported at $82,794. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.
Show as a table
| Year | Thomas Youm | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15,575 | $1,176 | $199–$4,249 | $163 |
| 2020 | $5,743 | $708 | $96–$2,890 | $114 |
| 2021 | $5,048 | $1,213 | $152–$3,994 | $132 |
| 2022 | $62,487 | $1,230 | $159–$3,998 | $149 |
| 2023 | $30,634 | $584 | $146–$2,836 | $160 |
| 2024 | $18,969 | $628 | $163–$3,168 | $164 |
| 2025 | $82,794 | $664 | $172–$3,055 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
95
Drug cost
$361
Branded share of claims
13.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 31 | $101 | |
| Naproxen | Generic | 23 | $91 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 13 | $86 | |
| Oxycodone Hcl | Generic | 15 | $70 | |
| Amoxicillin | Generic | 13 | $14 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 61 billing codesPaid by Medicare
$110,886
Medicare patients
246
Services billed
12,716
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 61% | |
| Ischemic heart disease | 26% | |
| Diabetes | 25% | |
| Osteoporosis | 21% | |
| Depression | 16% | |
| Cancer | 14% | |
| Atrial fibrillation | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 | Office | 21 | 11,760 | $5,033 |
| Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 | Office | 11 | 32 | $3,260 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 16 | 18 | $13 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
293 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in New Jersey
Related records
Sports Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.